Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors

Annals of Surgical Oncology

Volumn 14, Issue 2, 2007, Pages 780-785

  Jensen, Eric H ^a   Kvols, Larry ^a   McLoughlin, James M ^a   Lewis, James M ^a   Alvarado, Michael D ^a   Yeatman, Timothy ^a   Malafa, Mokenge ^a   Shibata, David ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

5HIAA; Carcinoid; Chromogrannin A; Debulking; Hepatic metastases; Serotonin

Indexed keywords

BIOLOGICAL MARKER; CHROMOGRANIN A; SEROTONIN;

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MALE; MEASUREMENT; MINIMAL RESIDUAL DISEASE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOID TUMOR; CATHETER ABLATION; CHROMOGRANIN A; DIGESTIVE SYSTEM NEOPLASMS; DISEASE PROGRESSION; FEMALE; HEPATECTOMY; HUMANS; HYDROXYINDOLEACETIC ACID; LIVER NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33846577777     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9148-z     Document Type: Article

References (29)

1. Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995; 425:547-560.
2. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15:966-973.
3. Oberndorfer Karzinoide tumoren des dunndarms. Franf Zschr Pathol 1907; 1:426-430.
4. Boudreaux JP, Putty B, Frey DJ, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005; 241:839-845; discussion 845-836.
5. Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005; 28:409-421.
6. Sartori P, Mussi C, Angelini C, et al. Palliative management strategies of advanced gastrointestinal carcinoid neoplasms. Langenbecks Arch Surg 2005; 390:391-396.
7. Akerstrom G, Hellman P, Hessman O, Osmak L. Management of midgut carcinoids. J Surg Oncol 2005; 89:161-169.
8. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg 2005; 241:776-783; discussion 783-775.
9. Westberg G, Wangberg B, Ahlman H, et al. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 2001; 88:865-872.
10. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89:151-160.
11. Feldman JM. Carcinoid tumors and the carcinoid syndrome. Curr Probl Surg 1989; 26:835-885.
12. Agranovich AL, Anderson GH, Manji M, et al. Carcinoid tumour of the gastrointestinal tract: prognostic factors and disease outcome. J Surg Oncol 1991; 47:45-52.
13. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8:685-690.
14. Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 1998; 43:223-228.
15. Taupenot L, Harper KL, OConnor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134-1149.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
17. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19:585-594.
18. Roche A, Girish BV, de Baere T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13:136-140.
19. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13:572-581.
20. Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177:337-341.
21. Oberg K. Biochemical diagnosis of neuroendocrine GEP tumor. Yale J Biol Med 1997; 70:501-508.
22. Ardill JE, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 2003; 10:459-462.
23. Nikou GC, Lygidakis NJ, Toubanakis C, et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 2005; 52:731-741.
24. Kolby L, Bernhardt P, Sward C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 2004; 120:269-273.
25. Kerstrom G, Hellman P, Hessman O. Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 2005; 19:717-728.
26. Makridis C, Ekbom A, Bring J, et al. Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 1997; 122:1075-1082.
27. Hellman P, Lundstrom T, Ohrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002; 26:991-997.
28. Ahlman H, Wangberg B, Jansson S, et al. Management of disseminated midgut carcinoid tumours. Digestion 1991; 49:78-96.
29. Wangberg B, Westberg G, Tylen U, et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 1996; 20:892-899; discussion 899.